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ABSTRACT
Bevacizumab is the irst-in-class antiangiogenic drug and is almost always 
administrated in combination with cytotoxics. Reports have shown that bevacizumab 
could induce a transient phase of vascular normalization, thus ensuring a better drug 
delivery when cytotoxics administration is adjuvant. However, determining the best 
sequence remains challenging. We have developed a mathematical model describing 
the impact of antiangiogenics on tumor vasculature. A 3.4 days gap between 
bevacizumab and paclitaxel was irst proposed by our model. To test its relevance, 84 
mice were orthotopically xenografted with human MDA-231Luc+ refractory breast cancer 
cells. Two sets of experiments were performed, based upon different bevacizumab 
dosing (10 or 20 mg/kg) and inter-cycle intervals (7 or 10 days), comprising several 
combinations with paclitaxel. Results showed that scheduling bevacizumab 3 days 
before paclitaxel improved antitumor eficacy (48% reduction in tumor size compared 
with concomitant dosing, p < 0.05) and reduced metastatic spreading. Additionally, 
bevacizumab alone could lead to more aggressive metastatic disease with shorter 
survival in animals. Our model was able to it the experimental data and provided 
insights on the underlying dynamics of the vasculature’s ability to deliver the cytotoxic 
agent. Final simulations suggested a new, data-informed optimal gap of 2.2 days. Our 
experimental data suggest that current concomitant dosing between bevacizumab 
and paclitaxel could be a sub-optimal strategy at bedside. In addition, this proof of 
concept study suggests that mathematical modelling could help to identify the optimal 
interval among a variety of possible alternate treatment modalities, thus reining the 
way experimental or clinical studies are conducted.
INTRODUCTION
Launched in 2004, bevacizumab has been approved 
since then in a variety of settings in solid tumors such as 
colorectal, breast, lung or ovarian cancers, with mixed 
and sometimes still questioned impact on survival [1]. Of 
note, bevacizumab has always only been approved as a 
concomitant administration with associated cytotoxics. 
Several studies from independent academic groups have 
suggested that anti-angiogenics could induce a transient 
phase or vasculature normalization with increased tumor 
blood perfusion, prior to exerting its antiangiogenics 
properties [2–6]. This paradoxical action has been 
considered as possibly generating a time-window to 
administrate chemotherapeutic agents, thus suggesting 
a paradigm shift from concomitant to sequential dosing. 
Indeed, delaying chemotherapy could allow higher 
quantities of drugs to reach the tumor, provided that their 
administration coincides with this normalization phase. As 
early as 2004, it has been shown that blocking VEGFR2 
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could decrease tumor hypoxia at the beginning of the 
treatment, thus demonstrating that transient normalization 
of tumor neo-vessels happens indeed with antiangiogenics 
[7, 8]. This was already associated with improved 
eficacy of combined radiotherapy or chemotherapy. 
Indeed, because disrupted tumor vasculature may lead 
to resistance to chemotherapy and radiotherapy due 
to subsequent higher interstitial luid pressure, and 
reduced blood low lowering drug delivery [9], alternate 
scheduling with antiangiogenics could overcome these 
resistances. Ever since, several groups have worked on 
this issue, mostly as part of experimental therapeutics 
[4, 6, 10]. Only few clinical trials have investigated on 
alternate scheduling with bevacizumab. The BRANCH 
study evaluated bevacizumab in rectal cancer patients 
after standard concomitant dosing or alternative 
sequential administration. Whereas concomitant dosing 
was little effective, the sequential administration led 
to 50% of tumor regression rate with 85% of 5-years 
survival and better tolerance [11]. These promising results 
supported the ongoing OBELICS study (Optimization of 
BEvacizumab scheduLIng within Chemotherapy Scheme), 
a phase-3 trial that will compare different sequences of 
bevacizumab associated with chemotherapy [12]. Despite 
these encouraging indings, the need for identifying proper 
biomarkers to forecast bevacizumab impact on neovessels 
remains critical [13] and until they are made available, 
in silico tools could be helpful to optimize alternate 
schedules. In contrast to the many pharmacodynamic 
models describing the action of cytotoxics on tumor 
growth [14], and despite substantial theoretical efforts in 
the ield of cancer modeling to simulate angiogenesis and 
tumor-vasculature interactions [15–18], relatively few 
mathematical models of anti-angiogenic therapy have been 
actually confronted to experimental data [19, 20], and even 
less have investigated combined effects of cytotoxics with 
antiangiogenics [20, 21]. To address this issue, our group has 
developed a phenomenological model describing the effect 
of antiangiogenics on vasculature quality throughout time, 
thus potentially forecasting when the normalization phase 
occurs [22]. When coupled with an eficacy component, 
this model should allow to compare in silico differences in 
eficacy depending on the lag-time between cytotoxics and 
antiangiogenics, thus helping in decision-making prior to 
start the actual experiments. As a proof-of-concept study, the 
aim of the present work was to confront model simulations 
with experimental data generated in a canonical refractory 
breast cancer mice model (i.e., MDA-MB231) treated with 
a standard combo between anti-angiogenics and cytotoxics 
(i.e. bevacizumab-paclitaxel doublet) in this setting. 
RESULTS
Based on our previous theoretical work [22] 
we performed simulations to inform the optimal time 
lag between the administrations of the two drugs 
(Supplementary Figures 1 and 2). These suggested 
an optimal gap of 3.4 days, leading to a putative 
reduction of 15.4% of the tumor mass as compared to a 
concomitant administration. Although based on parameter 
values that were not obtained from a quantitative it to 
experimental data, we used this value as a starting point 
and ixed a time lag of 3 days in the BEVA/TXL group 
of Experiment-1. In this experiment, no difference was 
observed in carcass weight among the different treatment 
groups (data not shown). Monitoring of tumor growth is 
shown in Figure 1A. At the end of the treatment phase 
(one week after the third cycle, i.e. D26), mean tumor 
mass expressed as % of initial mass were 6339 ± 1999 
(Control), 1270 ± 470 (Beva), 1222 ± 372 (TXL), 626 
± 234 (BEVA-TXL), 549 ± 245 (BEVA/TXL) and 2260 
± 553 (TXL/BEVA). A statistical difference was found 
between the groups (p = 0.007, Anova on the Ranks). 
Further Dunn’s multiple comparison testing showed that 
all treatment groups but BEVA and TXL/BEVA were 
different than Control (p < 0.05). At study conclusion 
(D78), mean tumor sizes (% of the initial mass) in the 
4 remaining groups were 5460 ± 2000 (TXL), 3857 
± 1370 (BEVA-TXL), 3560 ± 970 (BEVA/TXL) and 
8585 ± 4860 (TXL/BEVA). However, the differences 
between the remaining groups at study conclusion 
were not statistically signiicant (p = 0.788, Anova on 
Ranks). Survival curves for Experiment-1 are displayed 
in Figure 1B. Median survivals were 54 days (Control), 
60 days (BEVA), 68 days (TXL), 68 days (TXL/BEVA), 
74 days (BEVA/TXL) and 78 days (BEVA-TXL). A 
statistical difference in survival was found between the 
groups (p = 2.4 10-7), but further log rank testing showed 
that survival in the BEVA group was not different than 
Control (p = 0.0898), and no signiicant difference was 
evidenced between the BEVA/TXL and the BEVA-TXL 
groups (p = 0.214). Metastatic lesions were monitored and 
measured using 3D imaging (Supplementary Figure 3). 
Three main metastatic sites were found: lymph nodes, 
peritoneal carcinosis, and lungs. All the animals had 
at least one metastatic site. The kinetics of metastasis 
apparition throughout time is displayed in Figure 2C–2E. 
Marked differences were observed between the groups and 
the metastatic sites, both in terms of time and number of 
animals presenting with metastasis. In the Control group, 
100% of the mice developed metastasis and all animals 
developed secondary lesions on the 3 different sites. Time 
to reach 50% animals with at least one metastatic lesion 
were 29 days (Control), 33 days (BEVA, TXL, and TXL/
BEVA), 40 days (BEVA-TXL) and 47 days (BEVA/TXL). 
Metastasis-free survival analysis (log-rank) revealed a 
signiicant difference between all groups (p = 9.13 × 10-11, 
0.0031 and 1.73 × 10-9 for the axillary, peritoneal and lung 
locations, respectively). However, signiicant differences 
between the BEVA/TXL and BEVA-TXL groups were 
not obtained for any site. Nevertheless, only 30% of the 
mice had axillary node invasion at study conclusion in the 
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BEVA/TXL group versus 62.5% in the BEVA-TXL group. 
To further quantify the metastatic dynamics, a metastatic 
index was deined for each group and each location as 
the area under the cumulative incidence divided by the 
duration of the experiment (78 days in Experiment-1). 
This new metrics thus represents the average fraction of 
mice with metastasis over the experiment’s duration and 
is reported in Figure 1F. 
For Experiment-2, Figure 2A shows mean tumor 
growth among the groups expressed as % of initial mass. 
At the end of the treatment phase (one week after the 
third cycle, i.e. day 38), a signiicant difference was found 
between the groups (p = 0.032, Anova on the Ranks). 
Further Dunn’s multiple comparison testing showed 
that BEVA/TXL group, but not BEVA-TXL group, was 
different than Control (p < 0.05). At study conclusion 
(D52), mean tumor sizes (% of the initial mass) were 
19173 ± 9325 (Control), 10832 ± 2929 (BEVA-TXL), 
and 5186 ± 3341 (BEVA/TXL). A signiicant difference 
was found again between the groups (p = 0.012, Anova on 
the Ranks). Further Dunn’s multiple comparison testing 
showed that BEVA/TXL group, but not BEVA-TXL 
group, was different than Control (p < 0.05). The kinetic 
of metastasis apparition throughout time depending on 
the localization and the treatment group is displayed in 
Figure 3B–3D. At study conclusion, in the Control and 
Figure 1: Monitoring tumor growth, survival and metastatic spreading in Expe-1. Bevacizumab and paclitaxel were used at 
10 and 20 mg/kg I.P, respectively, with a 3 days lag when used sequentially. Three courses were administrated every 7 days (D5, D12, D19). 
Treatments were as following. Control: saline, BEVA: single angent bevacizumab, TXL: single agent paclitaxel, BEVA-TXL: bevacizumab 
and paclitaxel given concomitantly, BEVA/TXL: bevacizumab followed by paclitaxel, TXL/BEVA: paclitaxel followed by bevacizumab. 
(A). Tumor mass was evaluated by 2D bioluminescence imaging and expressed as % increase from initial measurement at D8. Values are 
mean ± s.e.m. (B). Survival. Mice were sacriiced when tumor volume reached an apparent mass of > 2g, or when signs for pain or distress 
were observed. Mice were imaged at 6 different wavelengths to discriminate different light-emitting sources on several plans. Secondary 
signals were gathered as 3 different groups: lymph nodes (C), peritoneal carcinosis (D) and lung metastasis (E, F). Metastatic indices (areas 
under the metastatic incidence curves) for the different groups and metastatic locations. 
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BEVA-TXL groups, 100% and 68% of the mice developed 
at least one metastasis whereas only 30% of the animals 
in the BEVA/TXL group displayed a metastasis. Time 
to reach 50% animals with at least one metastatic lesion 
was 38 days (Control), 52 days (BEVA-TXL) and was not 
reached by study conclusion for BEVA/TXL. Regarding the 
metastatic index, the BEVA/TXL group exhibited smaller 
values than BEVA-TXL for all locations (Figure 2E). The 
animals were necropsied at D60 to compare macroscopic 
search for metastatic lesions and 3D imaging. All the 
lesions previously identiied by bioluminescence were 
conirmed upon autopsy (data not shown). 
Our two mathematical models were able to it the 
data of Experiment-2, with model best-its falling within 
error bars for most of the measurements (Figure 3A 
and 3B). Resulting parameter values are reported in the 
Supplementary Table 1. Note that the growth and treatment 
parameters were kept the same among the groups and 
only the scheduling of the drugs was changed. The it of 
the simple model (1) allowed to quantitatively estimate 
improvement of vasculature quality due to bevacizumab 
and yielded a value of Q
–
 of 0.203 (Figure 3C), suggesting 
a 5-fold increase in drug delivery when bevacizumab was 
administered irst. Figure 3B shows further modeling using 
model (2) with dynamic and semi-mechanistic evolution 
of the quality of the vasculature depending on the vascular 
variables of the model. This last model allowed inference 
of unobserved quantities (such as U and S), generating 
insights on the dynamics of the system (Supplementary 
Figure 4). The dynamics of the quality of the vasculature 
Q revealed interesting patterns (Figure 3D). First, it 
exhibited an initial drop from a baseline value of 1 to a 
low quality, consistently with the reported poor quality 
of the tumor vasculature when untreated [8, 23–25]. 
Then, following the irst injection of bevacizumab, the 
number of unstable vessels U dropped (Supplementary 
Figure 4) while keeping a relatively constant level of 
stable vasculature S, resulting in an increase of the quality 
S
Q
S U
=
+
Interestingly, an unexpected effect occurred 
in the simulation, where two phases of vasculature 
Figure 2: Monitoring tumor growth and metastatic spreading in Expe-2. Both bevacizumab and paclitaxel were used at 
20 mg/kg I.P., respectively, with a 3 days delay when used sequentially. Three courses were administrated every 10 days (D11, D21, 
D31). Treatments were as following: Control: saline, BEVA-TXL: bevacizumab and paclitaxel given concomitantly, BEVA/TXL: 
bevacizumab followed by paclitaxel. (A) Tumor mass was evaluated by 2D bioluminescence imaging and expressed as % increase from 
initial measurement at D8. Values are mean ± s.e.m. Metastatic lesions were screened and quantitated by 3D bioluminescence imaging 
with DLIT reconstruction. (B): lymph node metastasis, (C): perinotenal carcinosis, (D): lung metastasis. (E). Metastatic indices Metastatic 
indices (areas under the metastatic incidence curves) for the different groups and metastatic locations.
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improvement were observed in the BEVA/TXL schedule 
(Figure 3D). The irst peak corresponds to the action of 
the bevacizumab alone on the reduction of U. The second 
and larger peak occurred approximately at the time of the 
cytotoxic injection. It can be explained as follows: the 
important decrease in V after the cytotoxics administration 
induced a loss in the stimulation term of the equation on 
U. The decrease was more pronounced in the stimulation 
term than in the inhibition term due to the 2/3 power in 
the latter. This translated into an important drop in U and 
therefore an increase of Q (Supplementary Figure 4 and 
Figure 3D). Eventually, we could generate a posteriori 
data-informed estimates of the best time window for 
the post-bevacizumab administration of paclitaxel 
(Figure 4). This gave a value of 2.2 days as the optimal 
gap between administrations of the two drugs, yielding 
a 68.3% tumor size reduction at day 52 when compared 
to the concomitant schedule, representing an additional 
16.5 points in size reduction. Interestingly, the model 
also predicted that some sequential schedules could be 
detrimental and provoke an increase when compared with 
the concomitant schedule, such as an 8 days gap (+13.6%).
DISCUSSION
Attempts to determine a better way to use 
bevacizumab are probably as old as the drug itself [26] and 
several non-clinical models have suggested that although 
Figure 3: Fits of models (1) (A) and (2) (B) to Expe-2 and resulting inferred quality of the vasculature (C) and (D). 
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empirical, alternate scheduling would perform better than 
standard concomitant dosing [4, 5, 8, 11, 26]. Recently, 
clinical data have shown that bevacizumab combined with 
carboplatin/nab-paclitaxel doublet yielded higher survival 
in patients with improved vascularization, probably 
through increased drug delivery of the nanoparticles [27]. 
Deining better sequencing between bevacizumab and 
cytotoxics can be done experimentally, i.e. by monitoring 
changes in vascular density, hypoxia or tumor blood low 
to determine next when the cytotoxics should be given, or 
in a merely empirical fashion, by testing and comparing 
different sequences in a trial-and-error mode. In this 
context, computational approaches could help, through in 
silico modeling, to determine rapidly the best scheduling 
among countless possibilities. For robustness purposes, 
and since our data was composed of macroscopic tumor 
growth kinetics, our mathematical model was deliberately 
kept to a minimal number of parameters and speciically 
designed for capturing normalization dynamics following 
the administration of bevacizumab. Both cytotoxic and 
anti-angiogenic properties of paclitaxel were integrated 
in our model (27). However, for the sake of practical 
usability and identiiability of the model, we skipped 
the thorough mechanistic description of the process 
as proposed by other models [15–18], or more detailed 
modeling of the anti-VEGF effect of bevacizumab [28, 
29] or paclitaxel tumor penetration [30]. Despite this, 
considerable standard errors remained in the estimation 
of the parameters, in part due to the large uncertainty in 
the measurement themselves, which is intrinsic to the 
measurement technique (kinetics of luciferin distribution 
in heterogeneous tumor mass). This generic model was 
customized to simulate a variety of sequences between 
bevacizumab and paclitaxel. We chose this doublet 
because it is the irst-line treatment for HER2-negative 
breast cancer extensively used in the clinics for a decade 
now [31]. Similarly, MDA-MB-231 was chosen as a 
canonical xenograft model for refractory breast cancer. 
In silico simulations irst suggested a 3.4 days lag-time 
when administrating bevacizumab and paclitaxel. For 
practical reasons, a sharp 3-days sequence was tested 
experimentally, and bevacizumab was administered I.P. 
because previous reports have demonstrated that drug 
distribution and antitumor eficacy after I.P. injection were 
equivalent to that of I.V. route [32]. In Experiment-1, both 
the BEVA-TXL and the BEVA/TXL groups displayed 
signiicantly reduced tumor growth as compared with all 
other treatment groups. However, despite a trend towards 
reduced tumor growth at treatment conclusion (–12%) 
and study conclusion (–9%), no statistical difference 
was found in eficacy or survival with the BEVA/TXL 
sequence over concomitant administration, much probably 
because of the sub-optimal dosing of bevacizumab in this 
irst experiment (i.e., 10 mg/kg). Of note, the reversed 
sequence TXL/BEVA showed limited eficacy because no 
statistical difference was found with Control at treatment 
conclusion, thus demonstrating that in addition to merely 
sequencing the dosing, the order of administration does 
matter indeed. Monitoring metastatic spreading showed 
marked differences among the groups with sometimes 
contradictory trends depending on the localization (Figure 
2C–2E). Of note, BEVA monotherapy seemed to increase 
the appearance of both lymph node and lung metastasis, 
and to a lesser extent of peritoneal carcinosis. This 
observation that antiangiogenics used alone could trigger 
early metastatic processes has already been reported with 
sunitinib in a renal carcinoma mice model [33]. However, 
this is the irst time that it is reported with bevacizumab, 
and this observation is in line with the signiicant shorter 
median survival (60 days) observed with the BEVA 
group. Based on this irst set of data, Experiment-2 was 
performed with slight changes to achieve a better eficacy 
with the BEVA/TXL sequence over the BEVA-TXL 
concomitant group. Bevacizumab dosing was doubled to 
20 mg/kg, and interval between two cycles was extended 
to 10 days. With this new setting, Experiment-2 showed 
Figure 4: Data-informed modeling simulations of various gaps between bevacizumab and paclitaxel administrations. 
The interval (gap) ranged from 0 (concomitant) to 8 days. (A) Tumor growth kinetics. (B) Final tumor fold increase as a function of the gap.
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that the BEVA/TXL sequence was more eficient with a 
statistically signiicant reduction of 48% and 53% of tumor 
growth as compared with concomitant dosing at the end of 
the treatment period and at study conclusion, respectively. 
Similarly, the BEVA/TXL sequence led to fewer and 
slightly delayed metastatic lesions, thus conirming the 
model predictions that delayed administration of paclitaxel 
achieves better antiproliferative eficacy. Based on the 
collected data, new model simulations suggested eventually 
that a 2.2 days delay (i.e., about 53 hours) should be used to 
administrate paclitaxel. Our model could easily be adapted 
to other drugs by changing the PK component adequately, 
which could lead to different optimal windows in other 
settings. Previous attempts to model combination therapies 
between antiangiogenics and cytotoxics had irst been 
merely theoretical, i.e. with no quantitative comparison to 
experimental data [15, 18, 34], apart from two recent studies 
[20, 21]. Here, our mathematical model was able to fully 
reproduce experimental data generated in xenografted mice, 
thus illustrating its robustness and the fact that although not 
mechanistic, it could mimic the different pharmacodynamic 
effects of the combination, depending on dosing and 
scheduling. As such, this model could be used in a 
prospective way to reine bevacizumab-based combinational 
regimen, rather than trying to ind an optimal sequence in 
an empirical fashion. Integrating modeling support is now 
a rising trend not only in basic research, but as well now in 
experimental and clinical oncology. To date, most resources 
in computational oncology have focused on developing 
highly sophisticated mechanistic models to better understand 
tumor biology. In addition to useful but complex multi-scale 
approaches, developing simpliied PK/PD models with 
tumor biology kept at its minimal expression to generate 
conigurable parameters is another appealing strategy [14]. 
Such simpliied phenomenological modeling has already 
proved to be capable of mimicking complicated phenomena 
[35] and its ability to be implemented at bedside [36–38]. 
Here, this proof-of-concept study strongly suggests that 
simpliied modeling could help to address the issue of inding 
the optimal dosing and scheduling with bevacizumab.
MATERIALS AND METHODS
Pharmacokinetics (PK) modeling
Plasma concentration of paclitaxel was described by 
a two-phase proile (absorption and elimination) and was 
characterized by a relatively fast elimination rate (terminal 
half-life of 3 hours) [39]. PK parameters of plasma distribution 
and elimination after intra-peritoneal administration were 
taken from [39]. The PK of bevacizumab was characterized 
by a one compartment model with absorption compartment 
[40]. Supplementary Figure 5 depicts the concentration 
proiles of the sequential and concomitant administrations for 
the second experiment and the PK equations. PK parameters 
are summarized in Supplementary Table 1. 
Pharmacodynamics (PD) modeling
To model the combined action of antiangiogenics 
and cytotoxics on tumor growth, we departed from the 
Hahnfeldt model that is able to take into account the effect 
of vasculature-targeting agents [19]. This model combines 
Gompertz growth for the tumor volume V(t) (with t 
denoting the time) with a dynamic carrying capacity K(t) 
(instead of a constant K in the classic Gompertz model). 
The dynamics of K(t) is governed by a balance between 
endogenous stimulation and inhibition of angiogenesis, 
with terms derived from biophysical considerations about 
diffusion rates of stimulatory/inhibitory agents. The effect 
of the cytotoxic drug (paclitaxel) was modeled similarly as 
in [41] where the authors considered a delay in the effect the 
drug, due to the fact that the cells are not directly removed 
after cytotoxic administration because they only die when 
reaching a speciic step of the cell cycle. After being affected 
by paclitaxel, the tumor cells thus stop proliferating and 
go through three compartments Z
1
, Z
2
 and Z
3
 before being 
removed from the system. Following reported observations, 
we considered that paclitaxel also had an anti-angiogenic 
effect [42]. Based on the literature [43], vascular endothelial 
cells were estimated to be approximately 5 times more 
sensitive to paclitaxel than tumor cells. The drugs delivery 
was assumed to be modulated by the vascular capacity, 
represented in the model by the variable K(t). Concentrations 
of the cytotoxic and antiangiogenic drugs (respectively 
denoted C(t) and A(t)) were given by their respective 
pharmacokinetics models and parameters. To quantify the 
effect of vascular normalization following bevacizumab 
therapy as the key element of this work, we introduced a 
new variable, the quality of the vasculature, denoted by 
Q. We irst considered a model where Q is constant in 
time and depends on the scheduling. The model writes:
( )
( )
( )
( )
( )
( )
2
3
0
1
1 1
2
1 2 2
3
2 3 3
1 2 3
ln 1
( 5 )  
0
0
0 
1
TXL I
BEVA CT I
TXL I
I
I
I
dV K
aV e KQCV V t
dt V
dK
bV dV K e e KQAK K t K
dt
dZ
e KQCV kZ Z t
dt
dZ
kZ kZ Z t
dt
dZ
kZ kZ Z t
dt
N V Z Z Z N t
  = − =   


= − − + =

 = − =


 = − =


= − =

= + + + =
 (1)
where V, K and Z
i
, i = 1,…,3 were expressed in 
normalized units by the initial bioluminescence signal 
corresponding to the number of injected cells. Thus, N 
represents the fold increase of the total number of cells to 
their initial value. Initial conditions at the irst observation 
time t
I
 was thus taken to 1 for V. For K, it was determined 
from a preliminary it to the control data only. Critically, in 
this irst model, the expression of Q was given by:
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for the BEVA TXL group1
for the BEVA / TXL group1
Q
Q
− <
= 

where Q  is a constant parameter to be estimated 
and BEVA-TXL and BEVA/TXL were respectively the 
concomitant and adjuvant paclitaxel groups.
The previous approach, although able to quantify 
the effect of vascular normalization on the drugs delivery 
improvement by means of ,Q  is not suited for modeling 
the dynamical changes of the vasculature quality, which 
are responsible for the optimal therapeutic window in the 
adjuvant administration of paclitaxel. Therefore, in line 
with previous theoretical modeling investigations [22], 
we enriched the model by means of a dynamic Q, linked 
to the tumor-vasculature system in a semi-mechanistic 
manner. Following biological rationales [8] and previous 
theoretical work [18], the principle was to divide the 
vasculature K(t) into two compartments: a stable one 
S(t) (mature vessels) and an unstable one U(t) (immature 
vessels), see Figure 5. The anti-angiogenic action of the 
drugs was assumed to occur on U (rather than S), because 
it represents the component of the vasculature directly 
affected by neo-angiogenesis, and especially by VEGF 
stimulation, which is the target of bevacizumab. Then, the 
(macroscopic) quality of the vasculature was deined as 
the ratio of the stable component of the vasculature over 
the total amount of blood vessels. The equations write:
( )
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Parameters estimation
The parameters were taken the same for all the 
groups, the only difference being the scheduling of the 
therapy, and were estimated in two steps. In the irst step, 
manual exploration of the parameter space was conducted 
in order to obtain visually acceptable it between the 
data and the model simulation. In a second step, an 
optimization algorithm based on the fminsearch function 
of Matlab (version R2015a, Mathworks Inc, Nelder-
Mead algorithm) was employed, following previously 
reported methods [44]. Data from all the groups were 
pooled together and the total sum of squared residuals was 
minimized. That is, denoting θ  the vector of parameters, 
we minimized the following objective function:
( ) ( )( )2
1 1
 , ,
G I
g
i i
g i
J y N t gθ θ
= =
= −∑∑
. 
where g stands for the group (scheduling) index 
ranging from l to G, i stands for the time point index 
ranging from l to I, 
g
iy  is the data point of group g at time 
t
i
 (mean over all the animals in the group). Due to the stiff 
PK proiles (Supplementary Figure 5), simulations were 
performed using the stiff ordinary differential equation 
solver ode15s of Matlab, with a relative tolerance of 10-9 
to avoid numerical issues. Preliminary it investigations 
constantly estimated τ  to a negligible value (< 10-10), 
consistently with the observations where no size decrease 
was obtained. Therefore, we ixed its value to zero but 
nevertheless kept it in the model as it could have nonzero 
value in other situations. Values of the parameters resulting 
from the its are reported in Supplementary Table 1. 
Cell lines
Triple negative human breast-cancer MDA-MB-
231-luc-D3H2LN cells were purchased from Perkin 
Elmer, France. Cells were used within 6 months upon 
reception. This BioWare light producing cell line was 
derived from the MDA-231 human adenocarcinoma by 
stable transfection of the North American irely gene 
expressed from the SV40 promoter. Upon reception, 
cells were gently thawed then immediately cultured per 
manufacturer recommendation (RPMI-1640 medium 
(Invitrogen) supplemented with 2 mmol/L l-glutamine 
(Invitrogen), 5 IU/mL penicillin/streptomycin (Eurobio), 
5 IU/mL fungizon (Eurobio), and 10% of FCS (Eurobio) 
at 37°C in a humidiied atmosphere with 5% CO2). Cells 
were next ampliied in culture lasks, trypsinized when 
in exponential phase and frozen into liquid nitrogen as 
stock cells. The cell line was regularly authenticated on 
the basis of viability, recovery, growth, morphology, and 
bioluminescence. 
Animal experiments
All experiments were submitted and approved by 
the local ethical committee of the institution (#CE14, Aix 
Marseille Univ) and the French Ministère de L’Education 
Nationale, de l ’Enseignement Supérieur et de la Recherche 
(MENESR) prior to starting the experiments. Experiments 
were conducted in compliance with European regulations, 
based on the UKCCCR guidelines for the welfare of 
animals in experimental oncology [45]. Pathogen-free, 
immuno-compromised 6-week-old female Nod Scid γ 
(NSG) mice (Charles River Laboratories, France) were 
kept in a sterile environment for 2 weeks upon reception. 
Mice were maintained in sterilized ilter-stopped cages 
kept in a sterile and thermostated cabinet throughout 
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the experiments. They were daily monitored for signs of 
distress, decreased physical activity or any behavioral 
change. Water was supplemented with paracetamol (eq. 
80 mg/kg/day) to prevent metastatic disease-related pain 
[46]. Animals were euthanized under anesthesia when 
showing signs of distress, cachexia (i.e., loss of 10% of 
body weight), or when tumor growth reached an apparent 
mass of 2 g (i.e., 2 cm3). Bodyweights were monitored 
twice a week as a surrogate marker for toxicity. 
Xenograft
MDA-MB-231 cells were trypsinized, counted, 
centrifuged (5 minutes, 1000 g) and washed twice with 
sterile PBS. Cells were re-suspended in RPMI-1640 with 
60% of Matrigel (BD Sciences France) and maintained in 
ice-cooled conditions until engraftment. A volume of 50 μL 
containing 80 000 cells (Experiment-1) and 120 000 cells 
(Experiment-2) was injected in the mammary inguinal 
right fat pad through the nipple under gas anesthesia (2% 
sevoluran, (Abbott France)). A total of 84 tumor-bearing 
mice were required to perform the experiments. However, 
90 mice were initially xenografted, to ensure that 48 
(Experiment-1) + 36 mice (Experiment-2) presenting with 
positive and measurable tumors could be used, taking into 
account an estimated 5% of possible failure during the 
grafting procedure.  
Bioluminescence imaging
Monitoring for both primary tumor growth and 
metastatic spreading started one week after engraftment. 
Intra-peritoneal injection of irely D-Luciferin (Perkin 
Elmer, 150 mg/kg) was performed in mice before 
starting imaging. Acquisitions started 12 minutes after 
Luciferine injection, the delay required to reach a plateau 
in bioluminescence signaling as shown in a previous 
study using the same mammary fat pad model [47]. For 
3D bioluminescence and search for metastatic lesions, 
images were acquired at six different wavelengths (560 
nm-660 nm) to discriminate signals depending on their 
depth. Acquisition and data processing were performed 
using IVIS Spectrum imager equipped with the Living 
Image 4.2 software (PerkinElmer). For Experiment-2, 
accuracy of the 3D imaging was compared with results 
from necroscopic examination at study conclusion. 
Treatments
In Experiment-1, 48 xenografted mice were divided 
into 6 treatment groups (n = 8 mice per group): control 
(saline injection), bevacizumab (BEVA), paclitaxel (TXL), 
bevacizumab + paclitaxel given concomitantly (BEVA-
TXL), bevacizumab followed by paclitaxel 3 days later 
(BEVA/TXL), paclitaxel followed by bevacizumab 
Figure 5: Scheme of the mathematical model (2).
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3 days later (TXL/BEVA). Treatments started 5 days after 
xenografting (D5). Dosing for bevacizumab and paclitaxel 
was 10 and 20 mg/kg respectively. A total of 3 cycles 
administered on a weekly basis were performed (i.e., D5, 
D12, D19). Based upon data collected from Experiment-1, 
a second set of experiment was performed, with slights 
changes in dosing, in sample size and inter-cure interval to 
increase statistical power and to maximize the differences 
between the groups. In Experiment-2, 36 xenografted 
mice were divided into 3 groups (n = 12 mice per 
group): control (saline), bevacizumab + paclitaxel given 
concomitantly (BEVA-TXL) and bevacizumab followed 
by paclitaxel 3 days later (BEVA/TXL). Treatment 
started 11 days after xenografting (D11). Dosing for 
bevacizumab and paclitaxel were 20 mg/kg for both 
drugs. A total of 3 cycles administered every 10 days was 
performed in Experiment-2 (i.e., D11, D21, D31). See the 
Supplementary Figure 6 for a summary of the schedules. 
All treatments were administered by intra-peritoneal route.
Statistical analysis
Inter-group differences in tumor growth were 
tested by One-Way Anova with Tukey’s HSD Post Hoc 
multiple comparison testing or Anova on Ranks with 
Dunn’s method according to data distribution, using 
Sigma Stat 4.0. software (Systat Software, Germany). 
We calculated a new metastatic index deined for each 
group and each location as the area under the cumulative 
incidence divided by the duration of the experiment, 
thus taking into account the dynamics of the metastatic 
spreading (the higher the index, the more aggressive the 
metastatic disease). Inter-group differences in survival 
were analyzed by log-rank testing (R software 3.2.2, R 
Core Team 2013, Vienna, Austria). Standard errors on the 
parameters estimates were computed using previously 
reported methods [44, 48].
CONCLUSIONS
In this pilot study, we have developed a simple 
phenomenological model that can be used to simulate 
the eficacy of different sequences between bevacizumab 
and paclitaxel, so as to determine the optimal scheduling 
between the drugs. This model has been voluntarily kept 
to a maximal simplicity so as to ensure its applicability. 
Although preliminary and performed on a single model, 
two separate mathematically-driven studies in tumor-
bearing mice showed that experimental data matched 
model predictions, thus conirming that delaying the 
administration of paclitaxel after that of bevacizumab 
improves the eficacy of this regimen. Beyond the 
present issue of reining bevacizumab/paclitaxel dosing 
and scheduling, our model could be further customized 
to mimic the PK/PD relationships of antiangiogenics 
associated with another chemotherapeutic regimen. 
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Model driven optimization of antiangiogenics + cytotoxics 
combination: application to breast cancer mice treated with 
bevacizumab + paclitaxel doublet leads to reduced tumor 
growth and fewer metastasis
Supplementary Materials
Supplementary Figure 1: Theoretical dynamics of the model (2) after a single injection of bevacizumab. Bevacizumab 
injection was simulated at day 0 with an initial tumor size of 2 × 108 cells and initial quality index of the vasculature of approximately 0.3. 
In these simulations, parameters were ixed from heuristic considerations [22].
Supplementary Figure 2: Theoretical simulation of the optimal window. (A) Simulations of the tumor kinetics proiles after 
administration of bevacizumab at day 0 and administration of paclitaxel after varying time delays (gaps). Model and parameters are from 
[22]. (B) Resulting end tumor size as a function of the gap between the two drugs administrations. Minimum is reached at 3.4 days.
Supplementary Figure 3: Study of metastatic spreading of MDA231-Luc+ bearing mouse by 3D bioluminescence 
imaging after DLIT reconstruction.
Supplementary Figure 4: Dynamics of immature and mature vasculature under the con- comitant and sequential 
administration schemes.
Supplementary Figure 5: Pharmacokinetics proile (Experiment-2). Pharmacokinetics (PK) proiles of bevacizumab and 
paclitaxel under the concomitant and sequential proiles.
PK of paclitaxel 
PK of paclitaxel was retrieved from [23]. It consists 
in a one-compartment model with absorption that writes: 
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where D is the administered dose of paclitaxel, V is 
the distribution volume, k
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is the elimination coeficient, N is the total number of drug 
administrations and t
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 are the paclitaxel administration 
times. These parameters are reported in the Supplementary 
Table 1. In relation to the half-life values reported in [23], 
the absorption and elimination coeficients are given by 
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PK of bevacizumab 
PK of bevacizumab was retrieved from [24]. It 
consisted also in a one-compartment absorption model 
(equation (1)) with adapted volume, absorption and 
elimination parameters, whose values can be found in 
Supplementary Table 1.
Supplementary Figure 6: Design of the schedules of the experiments.
Supplementary Table 1: Parameters estimates
Par. Unit Estimate SE (%) Ref.
PK TXL k
01
 day−1 23.8 - (22)
k
10
 day-1 5.55 - (22)
V ml 18.5 - (22)
PK BEVA k
01
 day−1 2.69 - (23)
k
10
 day-1 0.114 - (23)
V ml 2.38 - (23)
Model (1) a day-1 0.0786 0.0232 it
b day-1 1.21 0.358 it
d day-1 0.0202 - (41)
K
0
 - 38.6 - it
e
TXL
ml·mg-1·day-1 0.1 0.358 it
k day-1 0.328 51 it
e
BEVA
 ml·mg-1·day-1 0.0812 0.0694 it
 - 0.203 0.636 it
Model (2) a day-1 0.0703 0.0328 it
b day-1 86.8 463 it
d day-1 0.0745 0.508 (41)
χ day-1 0.00203 0.0164 it
τ day-1 0 - see text
U
0
- 5 50.5 it
S
0
- 82.4 116 it
e
TXL
ml·mg-1·day-1 13.9 84.3 it
k day-1 8.45x10-9 0.552 it
e
BEVA
 ml·mg-1·day-1 0.494 2.73 it
PK = pharmacokinetics. BEVA = bevacizumab. TXL = paclitaxel. ml = milliliters. biol. = biological rationale. SE = Standard 
Error on the parameter estimate. 
Note: parameter d was converted from reference (41) into relative units. Similarly, K0 was converted from a preliminary it 
to the control data set of experiment-1 and the number of injected cells converted into photons/sec.
